Cargando…
Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries?
Diabetes is a rapidly growing global health crisis disproportionately affecting low- and middle-income countries (LMICs). The emergence of diabetes as a global pandemic is one of the major challenges to human health, as long-term microvascular complications such as diabetic retinopathy (DR) can lead...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586227/ https://www.ncbi.nlm.nih.gov/pubmed/37868419 http://dx.doi.org/10.7759/cureus.45539 |
_version_ | 1785123113618374656 |
---|---|
author | Rizvi, Anza Rizvi, Fatima Lalakia, Parth Hyman, Leslie Frasso, Rosemary Sztandera, Les Das, Anthony Vipin |
author_facet | Rizvi, Anza Rizvi, Fatima Lalakia, Parth Hyman, Leslie Frasso, Rosemary Sztandera, Les Das, Anthony Vipin |
author_sort | Rizvi, Anza |
collection | PubMed |
description | Diabetes is a rapidly growing global health crisis disproportionately affecting low- and middle-income countries (LMICs). The emergence of diabetes as a global pandemic is one of the major challenges to human health, as long-term microvascular complications such as diabetic retinopathy (DR) can lead to irreversible blindness. Leveraging artificial intelligence (AI) technology may improve the diagnostic accuracy, efficiency, and accessibility of DR screenings across LMICs. However, there is a gap between the potential of AI technology and its implementation in clinical practice. The main objective of this systematic review is to summarize the currently available literature on the health economic assessments of AI implementation for DR screening in LMICs. The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We conducted an extensive systematic search of PubMed/MEDLINE, Scopus, and the Web of Science on July 15, 2023. Our review included full-text English-language articles from any publication year. The Joanna Briggs Institute's (JBI) critical appraisal checklist for economic evaluations was used to rate the quality and rigor of the selected articles. The initial search generated 1,423 records and was narrowed to five full-text articles through comprehensive inclusion and exclusion criteria. Of the five articles included in our systematic review, two used a cost-effectiveness analysis, two used a cost-utility analysis, and one used both a cost-effectiveness analysis and a cost-utility analysis. Across the five articles, LMICs such as China, Thailand, and Brazil were represented in the economic evaluations and models. Overall, three out of the five articles concluded that AI-based DR screening was more cost-effective in comparison to standard-of-care screening methods. Our systematic review highlights the need for more primary health economic analyses that carefully evaluate the economic implications of adopting AI technology for DR screening in LMICs. We hope this systematic review will offer valuable guidance to healthcare providers, scientists, and legislators to support appropriate decision-making regarding the implementation of AI algorithms for DR screening in healthcare workflows. |
format | Online Article Text |
id | pubmed-10586227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-105862272023-10-20 Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries? Rizvi, Anza Rizvi, Fatima Lalakia, Parth Hyman, Leslie Frasso, Rosemary Sztandera, Les Das, Anthony Vipin Cureus Ophthalmology Diabetes is a rapidly growing global health crisis disproportionately affecting low- and middle-income countries (LMICs). The emergence of diabetes as a global pandemic is one of the major challenges to human health, as long-term microvascular complications such as diabetic retinopathy (DR) can lead to irreversible blindness. Leveraging artificial intelligence (AI) technology may improve the diagnostic accuracy, efficiency, and accessibility of DR screenings across LMICs. However, there is a gap between the potential of AI technology and its implementation in clinical practice. The main objective of this systematic review is to summarize the currently available literature on the health economic assessments of AI implementation for DR screening in LMICs. The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We conducted an extensive systematic search of PubMed/MEDLINE, Scopus, and the Web of Science on July 15, 2023. Our review included full-text English-language articles from any publication year. The Joanna Briggs Institute's (JBI) critical appraisal checklist for economic evaluations was used to rate the quality and rigor of the selected articles. The initial search generated 1,423 records and was narrowed to five full-text articles through comprehensive inclusion and exclusion criteria. Of the five articles included in our systematic review, two used a cost-effectiveness analysis, two used a cost-utility analysis, and one used both a cost-effectiveness analysis and a cost-utility analysis. Across the five articles, LMICs such as China, Thailand, and Brazil were represented in the economic evaluations and models. Overall, three out of the five articles concluded that AI-based DR screening was more cost-effective in comparison to standard-of-care screening methods. Our systematic review highlights the need for more primary health economic analyses that carefully evaluate the economic implications of adopting AI technology for DR screening in LMICs. We hope this systematic review will offer valuable guidance to healthcare providers, scientists, and legislators to support appropriate decision-making regarding the implementation of AI algorithms for DR screening in healthcare workflows. Cureus 2023-09-19 /pmc/articles/PMC10586227/ /pubmed/37868419 http://dx.doi.org/10.7759/cureus.45539 Text en Copyright © 2023, Rizvi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Ophthalmology Rizvi, Anza Rizvi, Fatima Lalakia, Parth Hyman, Leslie Frasso, Rosemary Sztandera, Les Das, Anthony Vipin Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries? |
title | Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries? |
title_full | Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries? |
title_fullStr | Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries? |
title_full_unstemmed | Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries? |
title_short | Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries? |
title_sort | is artificial intelligence the cost-saving lens to diabetic retinopathy screening in low- and middle-income countries? |
topic | Ophthalmology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586227/ https://www.ncbi.nlm.nih.gov/pubmed/37868419 http://dx.doi.org/10.7759/cureus.45539 |
work_keys_str_mv | AT rizvianza isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries AT rizvifatima isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries AT lalakiaparth isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries AT hymanleslie isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries AT frassorosemary isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries AT sztanderales isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries AT dasanthonyvipin isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries |